– Scivita Medical Technology Co., Ltd. from Hong Kong is a maker of endoscopy products.
– The company received nearly RMB0.4 Billion in Series B financing.
– Backers included new investors such as Hudson Bay Capital Management and Prime Capital, as well as existing shareholders such as GL Ventures, Lilly Asia Ventures and Matrix Partners China.
– The new investment will be used for research and development, capacity expansion, and domestic and international commercialization of innovative products in endoscopy and related fields.

– Bota Bio has raised more than $100m in an oversubscribed Series B funding round.
– The financing was led by Sequoia Capital China.
– Other investors included previous backers Matrix Partners China, Source Code Capital, Sherpa Healthcare Partners, and 5Y Capital, among others.
– The new funds will be used to expand the company’s global operations and build out Bota Bio’s lab-to-pilot scale platform to facilitate the rapid scale-up and deployment of the company’s product pipeline in consumer goods, food, nutrition, and pharmaceutical products.

– PAQ Therapeutics is a biotechnology company advancing a new approach to restoring health and curing disease through autophagy.
– The company announced the closing of a $30m Series A round.
– Sherpa Healthcare Partners led the round with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund as well as seed investors Nest.Bio Ventures and Matrix Partners China.
– The funding will be used to advance the company’s ATTEC platform and progress its pipeline programs.

– Triastek, Inc. is a Nanjing, China-based global leader in 3D printed pharmaceuticals.
– The company raised $50m in Series B funding.
– This round was co-led by Matrix Partners China and CPE with participation from Shanghai Sci-Tech Innovation Center Capital (SSICC) and existing investors.
– Triastek intends to use the funds for ongoing development of the first IND-approved product in clinical trials, and expansion of the 3D printed drug product pipeline.

– NiKang Therapeutics Inc. announced the completion of an oversubscribed $200m series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital.
– All existing investors including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital participated in the financing.

– Taos Data is a Beijing, China-based IoT big data platform.
– The company closed $47m Series B financing.
– The round was led by Matrix Partners China, with participation from Sequoia Capital China, GGV Capital, and Index Capital.
– The new investment will be used for technology development and market expansion.

– DST is a Shenzen, China-based logistics electric vehicle (EV) operations platform.
– The company completed its latest round of Series C funding totalling $100m.
– The round was led by Ingka Investments (part of Ingka Group), followed by SMRT Ventures, China Securities Investment Capital and existing shareholders including Bojiang Capital and Matrix Partners China.
– The new investment will be used to add new capabilities to its digital platform, expand its maintenance network and enter international markets.

– Ronovo Surgical, an emerging medtech company focused on innovating minimally invasive (MIS) and digital surgery to address the tremendous needs of the Chinese surgical market, recently announced successful closing of Series A financing.
– The Series A financing was co-led by Matrix Partners China and Vivo Capital, with strong, continued support from seed investor Lilly Asia Ventures (LAV) and participation from GGV Capital.
– Developed by renowned surgeons, medtech veterans and robotics experts, Ronovo was founded in Shanghai in 2019 to establish a transformative technology platform that democratizes MIS and digital surgery in the vastly underserved Chinese surgical market.
– By focusing on the three pillars of simplicity, precision, and intelligence, Ronovo is positioning itself as a gateway to China for cutting edge MIS and digital surgery technology companies from around the world.

– OnQuality Pharmaceuticals LLC (“OnQuality”), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced the closing of its Series A+ financing round securing an additional $20 million in funding. This brings the total amount of capital raised in Series A and A+ to $35 million.
– This financing round included participation from Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, FreeS Fund, and additional biotech veterans.
– Proceeds from the financing will support the ongoing Phase II clinical trial of the company’s leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
OnQuality also announced the appointment of pharmaceutical executive Michael McCullar, Ph.

– Qihan Biotechnology Co. Ltd, a leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, announced today that it has raised an additional $67 million in Series A++ financing.
– Proceeds from the financing will primarily be used to advance Qihan’s pipeline of novel cell therapies in IND-enabling studies and hypoimmunity projects, and expansion of the company’s GMP manufacturing facilities.
– The financing was backed by new investors including leading biomedical venture capital firm, Lilly Asia Ventures and Matrix Partners China, as well as existing shareholders, Sequoia and CMB International.
– With these investments, Qihan’s total Series A financing raised to date has exceeded $100 million.